VASCADE
Commercial- Indications
- Small-bore femoral arterial and venous closure
Company intelligence / Profile preview
Cardiva Medical developed and commercialized the VASCADE portfolio of extravascular closure systems, which were clinically proven to reduce access site complications compared to manual compression. Their products were FDA-approved and CE-marked, with demonstrated improvements in patient outcomes and hospital workflow. The company was acquired by Haemonetics Corporation in March 2021 for $510 million.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cardiva Medical.